Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TGRX-678 in Refractory or Advanced CML
NCT05434312Phase 1Active, not recruiting
- Sponsor
- Shenzhen TargetRx
- Start
- Mar 2021
- Primary completion
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of TGRX-678 in chronic myelogenous leukemia (CML), sponsored by Shenzhen TargetRx. Primary endpoints: Maximal Tolerated Dose, Recommended Phase II Dose and 2 more. Started Mar 2021; status: active, not recruiting.
02
Drugs
TGRX-678
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on NCT05434312.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05434312.